Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against sars-cov-2 xbb.1.5

1. Lasrado, N. et al. Waning immunity and IgG4 responses following bivalent mRNA boosting. Sci. Adv. 10, 9945 (2024).

   Google Scholar 

2. Föhse, K. et al. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses. Clin. Immunol. 255, 109762 (2023).

   Google Scholar 

3. Ishii, T. et al. Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination. Sci. Rep. 13, 1–12 (2023).

   Google Scholar 

4. Haq, M. A. et al. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh. Sci. Rep. 14, 1–11 (2024).

   Google Scholar 

5. Tong, X. et al. Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination. Nat. Commun. 14, 1–15 (2023). 2023 14:1.

   Google Scholar 

6. Moore, M., Anderson, L., Schiffer, J. T., Matrajt, L. & Dimitrov, D. Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis. Vaccine 54, 126966 (2025).

   Google Scholar 

7. Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587–599.e4 (2024).

   Google Scholar 

8. Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80–82 (2021).

   Google Scholar 

9. Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N. Engl. J. Med. 384, 2259–2261 (2021).

   Google Scholar 

10. Pegu, A. et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science (1979) 373, 1372–1377 (2021).

    Google Scholar 

11. Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141–145 (2022).

    Google Scholar 

12. Nguyen, D. C. et al. SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination. Nat. Med. 31, 235–244 (2025).

    Google Scholar 

13. Florea, A. et al. Effectiveness of messenger RNA-1273 vaccine booster against coronavirus disease 2019 in immunocompetent adults. Clin. Infect. Dis. 76, 252–262 (2023).

    Google Scholar 

14. Abu-Raddad, L. J. et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N. Engl. J. Med. 386, 1804–1816 (2022).

    Google Scholar 

15. Ackerson, B. K. et al. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. Hum Vaccin. Immunother. 20, 2335052 (2024).

16. Maslow, J. N. et al. DNA vaccines for epidemic preparedness: SARS-CoV-2 and beyond. Vaccine 11, 1016 (2023).

    Google Scholar 

17. Blakney, A. K. & Bekker, L. G. DNA vaccines join the fight against COVID-19. Lancet 399, 1281–1282 (2022).

    Google Scholar 

18. Feliciano, L. – et al. Improved DNA vaccine delivery with needle-free injection systems. Vaccines 11, 280 (2023).

    Google Scholar 

19. Sabnis, S. et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509–1519 (2018).

    Google Scholar 

20. Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).

    Google Scholar 

21. Connors, J. et al. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. Commun. Biol. 6, 1–13 (2023).

    Google Scholar 

22. Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021).

    Google Scholar 

23. Pfeifle, A. et al. DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice. Front Immunol. 14, 1020134 (2023).

    Google Scholar 

24. Guimaraes, L. C. et al. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Nat. Commun. 15, 1–19 (2024). 2024 15:1.

    Google Scholar 

25. Liao, H. C. et al. Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters. Mol. Ther. Methods Clin. Dev. 32, 101169 (2024).

    Google Scholar 

26. Tursi, N. J. et al. Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. Cell Rep. Med 6, 102035 (2025).

    Google Scholar 

27. Li, M. et al. Lipid nanoparticles outperform electroporation in delivering therapeutic HPV DNA vaccines. Vaccines (Basel) 12, 666 (2024).

    Google Scholar 

28. Zhang, W. et al. The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice. Vaccines (Basel) 11, 1580 (2023).

    Google Scholar 

29. Patel, M. N. et al. Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids. Nat. Biotechnol. 2025 1–11 https://doi.org/10.1038/s41587-025-02556-5 (2025).

30. F. D. A. Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants | FDA. https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating.

31. Tamming, L. A. et al. DNA based vaccine expressing SARS-CoV-2 Spike-CD40L fusion protein confers protection against challenge in a Syrian Hamster Model. Front Immunol 12, 785349 (2022).

32. Tamming, L. et al. Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters. Mol. Ther. Methods Clin. Dev. 32, 101325 (2024).

    Google Scholar 

33. Kaku, Y., Uriu, K., Okumura, K., Ito, J. & Sato, K. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect. Dis. 24, e609 (2024).

    Google Scholar 

34. Nunes da Silva, W., Dias Moura Prazeres, P. H. & Goulart Guimarães, P. P. PLA-PEG as an alternative to PEGylated lipids for nanoparticle-based DNA vaccination against SARS-CoV-2. Mol. Ther. Nucleic Acids 35, 102293 (2024).

    Google Scholar 

35. Lai, D. C., Nguyen, T. N., Trinh, G. P., Steffen, D. & Vu, H. L. X. Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies. J. Virol. https://doi.org/10.1128/JVI.01123-25 (2025).

    Google Scholar 

36. Lai, D. C., Nguyen, T. N., Poonsuk, K., McVey, D. S. & Vu, H. L. X. Lipid nanoparticle-encapsulated DNA vaccine encoding African swine fever virus p54 antigen elicits robust immune responses in pigs. Vet. Microbiol 305, 110508 (2025).

    Google Scholar 

37. Mucker, E. M. et al. Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines. Sci. Rep. 10, 8764 (2020).

    Google Scholar 

38. AM, H. et al. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus. J. Immunol. 193, 722–734 (2014).

    Google Scholar 

39. Kometani, K. & Kurosaki, T. Differentiation and maintenance of long-lived plasma cells. Curr. Opin. Immunol. 33, 64–69 (2015).

    Google Scholar 

40. Brook, B. et al. Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70. Sci. Transl. Med. 16, eadm8451 (2024).

41. Wang, L. et al. IL-7 promotes mRNA vaccine-induced long-term immunity. Immun. J. Nanobiotechnology 22, 716 (2024).

    Google Scholar 

42. Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Controlled Release 217, 345–351 (2015).

    Google Scholar 

43. Swingle, K. L. et al. Circular RNA lipid nanoparticle vaccine against SARS-CoV-2. Proc. Natl. Acad. Sci. 122, e2505718122 (2025).

    Google Scholar 

44. Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728–1744.e16 (2022).

    Google Scholar 

45. Wan, J. et al. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. mBio 15, e0177523 (2024).

46. Krawczyk, P. S. et al. Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines. Nature 641, 984–992 (2025).

    Google Scholar 

47. Robinson, M. J. et al. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response. Sci Immunol 7, eabm8389 (2022).

48. Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853–1868.e7 (2021).

    Google Scholar 

49. Colwill, K. et al. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin. Transl. Immunol. 11, e1380 (2022).

    Google Scholar 

50. Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699–3715 (2020).

    Google Scholar 

51. Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).

    Google Scholar 

52. Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).

    Google Scholar 

53. Zivcec, M., Safronetz, D., Haddock, E., Feldmann, H. & Ebihara, H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Methods 368, 24–35 (2011).

    Google Scholar 

54. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 − ΔΔCT method. Methods 25, 402–408 (2001).

    Google Scholar 

55. Harris, G., Holbein, B. E., Zhou, H., Howard Xu, H. & Chen, W. Potential mechanisms of mucin-enhanced acinetobacter baumannii virulence in the mouse model of intraperitoneal infection. Infect Immun 87, e00591–19 (2019).

56. Lien, C. E. et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Sci. Rep. 2021 11, 1–7 (2021).

    Google Scholar 

Download references

Authors and Affiliations

1. Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada

   Levi Tamming, Casey Lansdell, Wanyue Zhang, Grant Frahm, Annabelle Pfeifle, Sathya N. Thulasi Raman, Jianguo Wu, Caroline Gravel, Andrew Stalker, Simon Sauve, Michael J. W. Johnston & Xuguang Li

2. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

   Levi Tamming, Wanyue Zhang, Annabelle Pfeifle, Lisheng Wang, Anh Tran & Xuguang Li

3. Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON, Canada

   Diana Duque, Jegarubee Bavananthasivam, Wangxue Chen & Anh Tran

4. Human Health Therapeutics Research Center, National Research Council of Canada, Montreal, QC, Canada

   Matthew Stuible & Yves Durocher

5. Department of Chemistry, Carleton University, Ottawa, ON, Canada

   Michael J. W. Johnston

Contributions

Conceptualization, L.T., A.T., M.J.W.J., X.L.; Methodology, L.T., C.L., W.Z., G.F., M.S., A.T.; Formal Analysis and Visualization, L.T., A.S.; Investigation, L.T., C.L., W.Z., D.D., J.B., G.F., A.P., S.N.R. J.W., C.G., A.S., W.C.; Resources, C.L., S.N.R., C.G., M.S., Y.D., A.T.; Writing—Original Draft, L.T.; Writing—Review & Editing, L.T., C.L., W.Z., D.D., J.B., G.F., A.P., S.N.R. J.W., C.G., A.S., M.S., Y.D., W.C., L.W., S.S., A.T., M.J.W.J., X.L.; Supervision, Y.D., L.W., S.S., A.T., M.J.W.J., X.L.; Project Administration L.T., A.T., M.J.W.J., X.L.; Funding Acquisition, Y.D., L.W., S.S., A.T., M.J.W.J., X.L.

Corresponding authors

Correspondence to Anh Tran, Michael J. W. Johnston or Xuguang Li.

Competing interests

The authors declare no Competing Financial or Non-Financial Interests to declare.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions